ABSTRACT
Unintentional transfer between a dosed individual and his or her interpersonal contacts is documented (17-19). Although transdermal delivery of estradiol and testosterone is clinically relevant for the treated individual, unintentional interpersonal transfer can cause hormone imbalance and adverse effects. These imbalances may increase adverse cardiac event risk in men; cause hyperandrogenism, hirsutism, acne, voice coarsening, clitoris hypertrophy, and male-pattern baldness in women; and precocious puberty, virilization, and premature epiphyseal plate closure in children (20-28). Such adverse events have gained notice in the public eye and have led to U.S. Food and Drug Administration (FDA) issued black box warnings on transdermal hormone products.
